2026-04-17T00:59:40Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4775992025-08-31T17:25:45Zcom_2072_98col_2072_378192

SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022) Pérez-Segura, Pedro Vilariño, Noelia Martínez García, María Del Barco Berrón, Sonia Gironés, Regina García Gómez, Jesús García Castaño, Almudena Navarro Martín, Luis Miguel Gallego Rubio, Oriol Pineda, Estela Universitat Autònoma de Barcelona Epidemiology High-grade gliomas Management Molecular Treatment High-grade gliomas (HGG) are the most common primary brain malignancies and account for more than half of all malignant primary brain tumors. The new 2021 WHO classification divides adult HGG into four subtypes: grade 3 oligodendroglioma (1p/19 codeleted, IDH-mutant); grade 3 IDH-mutant astrocytoma; grade 4 IDH-mutant astrocytoma, and grade 4 IDH wild-type glioblastoma (GB). Radiotherapy (RT) and chemotherapy (CTX) are the current standard of care for patients with newly diagnosed HGG. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent high-grade gliomas is not well defined and decision-making is usually based on prior strategies, as well as several clinical and radiological factors. Whereas the prognosis for GB is grim (5-year survival rate of 5-10%) outcomes for the other high-grade gliomas are typically better, depending on the molecular features of the tumor. The presence of neurological deficits and seizures can significantly impact quality of life. 2023 Article Clinical & translational oncology ; Vol. 25 Núm. 9 (september 2023), p. 2634-2646 open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/